COMP <GO>
SMMT vs ELAN // 10Y YIELD & FRED MACRO BETA
Summit Therapeutics Inc. (NASDAQ) VS. Elanco Animal Health Incorporated (NYSE) • 15-METRIC TALLY: SMMT 3
— ELAN 8
▲ 10Y YIELD & FRED MACRO BETA LEADER: SMMT
LAST: $15.80 (+6.76%) • MKT CAP: $11.84B
macro-sensitivity
0.97
LAST: $24.57 (+1.95%) • MKT CAP: $12.04B
macro-sensitivity
0.96
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SMMT VS. ELAN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SMMT | ELAN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 55.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -2.50% | -32.50 | ELAN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.50% | 2.45% | -4.95 | ELAN | /fcf-yield <GO> |
| Operating Margin | -36.30% | -6.00% | -30.30 | ELAN | /operating-margins <GO> |
| Net Profit Margin | -29.80% | -4.90% | -24.90 | ELAN | /net-margins <GO> |
| Revenue Growth (YoY) | 11.00% | 6.20% | +4.80 | SMMT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 1.24 | +24.76 | SMMT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ELAN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.4 | 63.3 | -21.90 | ELAN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.97 | 0.96 | +0.01 | SMMT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.0x | 20.0x | +14.00 | ELAN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.84B | $12.04B | -$204.9M | ELAN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SMMT REV | ELAN REV | SMMT GROSS % | ELAN GROSS % | SMMT FCF | ELAN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.57B | $4.71B | — | 55.0% | -$323.6M | $284.0M |
| FY 2024 | $632.8M | $4.44B | — | 54.9% | -$142.2M | $394.0M |
| FY 2023 | $1.71B | $4.42B | — | — | -$76.8M | $72.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SMMT // BETA 0.97
ELAN // BETA 0.96